Long title
A randomized, placebo-controlled trial, to evaluate the safety and immunogenicity of the COVID-19 vaccine, a measles vector-based vaccine candidate against COVID-19 in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase.
Date receipt dossier
EU record number
COVID-19-101
EudraCT number
2020-002973-89
Company / Sponsor
Institut Pasteur & Themis Bioscience GmbH
Phase
I
Treated organism
Humans
Indication category
Infectious disease
Disease
COVID-19
Therapeutic approach
Prevention
Genetic modification
Recombinant measles virus vaccine strain (Schwarz strain) expressing the Spike glycoprotein 1 from SARS-CoV2
Method of transfer of nucleic acid of interest
Not applicable
Administered biological material
Recombinant measles virus vaccine strain (Schwarz strain) expressing the Spike glycoprotein 1 from SARS-CoV2
Route of administration
Intramuscular
Locations in Belgium
SGS Belgium
Type of procedure
Contained use only
Current status
Under evaluation
Pharmaceutical study code
MV-SARS-Cov2